- Home
- INLX vs PRLD Comparison
INLX vs PRLD Comparison
Compare INLX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INLX
- PRLD
- Stock Information
- Founded
- INLX 1996
- PRLD 2016
- Country
- INLX United States
- PRLD United States
- Employees
- INLX N/A
- PRLD N/A
- Industry
- INLX EDP Services
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- INLX Technology
- PRLD Health Care
- Exchange
- INLX Nasdaq
- PRLD Nasdaq
- Market Cap
- INLX 60.5M
- PRLD 50.1M
- IPO Year
- INLX N/A
- PRLD 2020
- Fundamental
- Price
- INLX $14.47
- PRLD $0.82
- Analyst Decision
- INLX
- PRLD Strong Buy
- Analyst Count
- INLX 0
- PRLD 2
- Target Price
- INLX N/A
- PRLD $4.50
- AVG Volume (30 Days)
- INLX 3.5K
- PRLD 111.3K
- Earning Date
- INLX 05-16-2025
- PRLD 05-06-2025
- Dividend Yield
- INLX N/A
- PRLD N/A
- EPS Growth
- INLX N/A
- PRLD N/A
- EPS
- INLX N/A
- PRLD N/A
- Revenue
- INLX $18,018,373.00
- PRLD $7,000,000.00
- Revenue This Year
- INLX $7.58
- PRLD N/A
- Revenue Next Year
- INLX N/A
- PRLD N/A
- P/E Ratio
- INLX N/A
- PRLD N/A
- Revenue Growth
- INLX 6.70
- PRLD N/A
- 52 Week Low
- INLX $5.85
- PRLD $0.61
- 52 Week High
- INLX $16.50
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- INLX 55.56
- PRLD 50.23
- Support Level
- INLX $12.00
- PRLD $0.73
- Resistance Level
- INLX $14.99
- PRLD $1.00
- Average True Range (ATR)
- INLX 0.67
- PRLD 0.09
- MACD
- INLX -0.09
- PRLD -0.01
- Stochastic Oscillator
- INLX 66.40
- PRLD 32.60
About INLX Intellinetics Inc.
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.